Tired of seeing most of the $1 billion-plus it raised for startup funding leave the state, Johns Hopkins University has opened a new state-of-the-art technology incubation hub, part of a $65 million expansion project.
If there was any doubt that a Republican-led Congress might give a strong boost to federal science spending, the Trump administration probably sealed the deal.
With its call in March for a mammoth $6-billion cut in the annual budget of the National Institutes of Health, the administration appears to have done more than anything else to energize the science community and supportive lawmakers, advocates said.
NHLBI small business awardees are eligible to apply for a competing revision to your current award. The Regenerative Medicine Innovation Project (RMIP), will support revision projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies.
Awards are anticipated in FY 2017
GSK today announced $139 million of new investment in its biopharmaceutical manufacturing site in Rockville, MD to support growing demand for BENLYSTA® (belimumab) for adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.
The National Institutes of Health will get a $2 billion funding boost over the next five months, under a bipartisan spending deal reached late Sunday night in Congress. The agreement marks a sharp rejection of President Trump’s proposal to cut $1.2 billion from the medical research agency in the current fiscal year.
For Charles Li, locating his office at the Johns Hopkins University Montgomery County Campus is like coming home.
Li received his MBA from the Carey Business School in 2014 and took the majority of his classes at the Rockville campus. Three years later, when presented with the opportunity to open a business office in Maryland, he chose JHU MCC. He likes the campus library and the proximity to his house.
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced topline clinical results from a small, proof-of-concept clinical trial sponsored by the National Institute of Mental Health (“NIMH”) of the National Institutes of Health. This was a Phase 2 trial of CERC-501, a potent and selective oral kappa opioid receptor (“KOR”) antagonist, in treatment resistant depression (“TRD”) conducted under the leadership of Dr. Maurizio Fava of Massachusetts General Hospital (“MGH”).
On Saturday, hundreds of thousands of people are expected to march in Washington, DC, to celebrate and defend science—at a time when many believe that science does, in fact, need defending. President Trump’s budget proposal cuts 31 percent from the Environmental Protection Agency, slashes the Department of Energy’s basic science research program, and zeroes out a program that supports early-stage research into technologies that can reduce our national dependence on fossil fuels. The National Institutes of Health (NIH), which spends $32 billion a year on biomedical research — most of which is undertaken in labs at universities and medical schools across the nation — would see a 20 percent cut, bringing the agency’s budget to its lowest level in 15 years. Beyond science, the president’s proposed budget also eliminates the National Endowment for the Arts and the National Endowment for the Humanities.
VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that it successfully received a notice of allowance from the U.S. Patent and Trademark Office for the composition of matter patent to cover immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP. The patent will be issued on May 2nd. The patent protects key composition of matter of VLP’s proprietary i-α virus like particles platform technology, and the pharmaceutical composition and vaccine for use in the treatment of cancer. Utilizing the platform technology covered by this patent and other patent estates, VLP is currently focused on developing preventative and therapeutic cancer vaccines as well as next generation of targeted antibody agents.
Silver Spring-based United Therapeutics Corp. has been clear about its ambitions to build an unlimited supply of certain transplantable organs.
Now, founder Martine Rothblatt said the company’s new multiyear collaboration with a 3-D bioprinting company, announced Wednesday, takes it a big step toward that goal.